journal article·2024-06-27Open access

Radiological Reporting Systems in Multiple Sclerosis

Alessandra Scaravilli, Mario Tranfa, Giuseppe Pontillo, Antonio Carotenuto, Caterina Lapucci, Riccardo Nistri, Elisabetta Signoriello, Marcello Moccia, Carla Tortorella, Ruggero Capra, Giacomo Lus, Matilde Inglese, Claudio Gasperini, Roberta Lanzillo, Carlo Pozzilli, Vincenzo Brescia Morra, Arturo Brunetti, Maria Petracca, Sirio Cocozza

Applied Sciences· Volume 14· Issue 13

Abstract

(1) Background: Although MRI is a well-established tool in Multiple Sclerosis (MS) diagnosis and management, neuroradiological reports often lack standardization and/or quantitative information, with possible consequences in clinical care. The aim of this study was to evaluate the impact of information provided by neuroradiological reports and different reporting systems on the clinical management of MS patients. (2) Methods: An online questionnaire was proposed to neurologists working in Italian tertiary care level MS centers. Questions assessed the impact of different MRI-derived biomarkers on clinical choices, the preferred way of receiving radiological information, and the neurologists’ opinions about different reporting systems and the use of automated software in clinical practice. (3) Results: The online survey was completed by 62 neurologists. New/enlarging (100%) lesions, the global T2w/FLAIR lesion load (96.8%), and contrast-enhancing (95.2%) lesions were considered the most important biomarkers for therapeutic decision, while new/enlarging lesions (98.4%), global T2w/FLAIR lesion load (96.8%), and cerebral atrophy (90.3%) were relevant to prognostic evaluations. Almost all participants (98.4%) considered software for medical imaging quantification helpful in clinical management, mostly in relation to prognostic evaluations. (4) Conclusions: These data highlight the impact of providing accurate and reliable data in neuroradiological reports. The use of software for medical imaging quantification in MS can be helpful to standardize radiological reports and to provide useful clinical information to neurologists.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Radiation Dose and Imaging · Lung Cancer Treatments and Mutations · Advanced Radiotherapy Techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Advanced Biomedical Sciences, University “Federico II”, 80131 Naples, Italy

Department of Electrical Engineering and Information Technology, University “Federico II”, 80138 Naples, Italy

Department of Neurosciences and Reproductive and Odontostomatological Sciences, University “Federico II”, 80131 Naples, Italy

IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy

Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, 16132 Genoa, Italy

Department of Human Neurosciences, Sapienza University, 00185 Rome, Italy

Department of Advanced Medical and Surgical Sciences, II Division of Neurology, Multiple Sclerosis Center, University of Campania “L. Vanvitelli”, 80138 Naples, Italy

Department of Molecular Medicine and Medical Biotechnology, Multiple Sclerosis Clinical Unit, University “Federico II”, 80131 Naples, Italy

Multiple Sclerosis Centre, Department of Neurosciences, San Camillo-Forlanini Hospital, 00149 Rome, Italy

Multiple Sclerosis Centre, Department of Neurology, Spedali Civili, 25123 Brescia, Italy

References (40)

Show source-provided references
1. Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: Recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society10.1111/ane.12667 ↗
2. Update on brain MRI for the diagnosis and follow-up of MS patients10.1016/j.lpm.2021.104067 ↗
3. Unraveling treatment response in multiple sclerosis A clinical and MRI challenge10.1212/WNL.0000000000006810 ↗
4. 2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis10.1016/S1474-4422(21)00095-8 ↗
5. Structured Reporting in Multiple Sclerosis—Consensus-Based Reporting Templates for Magnetic Resonance Imaging of the Brain and Spinal Cord10.1055/a-1867-3942 ↗
6. Radiologist Preferences, Agreement, and Variability in Phrases Used to Convey Diagnostic Certainty in Radiology Reports10.1016/j.jacr.2018.09.052 ↗
7. Measurement of Whole-Brain and Gray Matter Atrophy in Multiple Sclerosis: Assessment with MR Imaging10.1148/radiol.2018172468 ↗
8. Structured Reporting in Multiple Sclerosis Reduces Interpretation Time10.1016/j.acra.2020.08.006 ↗
9. Do MRI Structured Reports for Multiple Sclerosis Contain Adequate Information for Clinical Decision Making?10.2214/AJR.17.18451 ↗
10. Neurodegeneration in multiple sclerosis10.1002/wsbm.1583 ↗
11. Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis10.1136/jnnp-2019-322348 ↗
12. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions10.1177/1352458518814117 ↗
13. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque10.1002/ana.24497 ↗
14. Immunopathology of secondary-progressive multiple sclerosis10.1002/ana.1255 ↗
15. Association of Chronic Active Multiple Sclerosis Lesions with Disability In Vivo10.1001/jamaneurol.2019.2399 ↗
16. Slow expansion of multiple sclerosis iron rim lesions: Pathology and 7 T magnetic resonance imaging10.1007/s00401-016-1636-z ↗
17. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis10.1093/brain/awz212 ↗
18. Expansion of chronic lesions is linked to disease progression in relapsing-remitting multiple sclerosis patients10.1177/1352458520974357 ↗
19. Mechanisms of central brain atrophy in multiple sclerosis10.1177/13524585221111684 ↗
20. Honce, J.M., Nair, K.V., Hoyt, B.D., Seale, R.A., Sillau, S., Engebretson, E., Schurr, B., Corboy, J.R., Vollmer, T.L., and Alvarez, E. (2020). Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate. Front. Neurol., 11.10.3389/fneur.2020.01045 ↗
21. Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis10.1177/1352458515616701 ↗
22. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis10.1002/ana.24018 ↗
23. Progression of regional grey matter atrophy in multiple sclerosis10.1093/brain/awy088 ↗
24. The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain10.1093/brain/awv398 ↗
25. Stratification of multiple sclerosis patients using unsupervised machine learning: A single-visit MRI-driven approach10.1007/s00330-022-08610-z ↗
26. Progression of regional atrophy in the left hemisphere contributes to clinical and cognitive deterioration in multiple sclerosis: A 5-year study10.1002/hbm.23755 ↗
27. Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant10.1093/brain/awv337 ↗
28. Determinants of Deep Gray Matter Atrophy in Multiple Sclerosis: A Multimodal MRI Study10.3174/ajnr.A5915 ↗
29. Thalamic atrophy in multiple sclerosis: A magnetic resonance imaging marker of neurodegeneration throughout disease10.1002/ana.25150 ↗
30. Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis10.1002/ana.26281 ↗
31. Hänninen, K., Viitala, M., Paavilainen, T., Karhu, J.O., Rinne, J., Koikkalainen, J., Lötjönen, J., and Soilu-Hänninen, M. (2019). Thalamic Atrophy Without Whole Brain Atrophy Is Associated with Absence of 2-Year NEDA in Multiple Sclerosis. Front. Neurol., 10.10.3389/fneur.2019.00459 ↗
32. A matter of atrophy: Differential impact of brain and spine damage on disability worsening in multiple sclerosis10.1007/s00415-021-10576-9 ↗
33. Thalamic atrophy and cognitive impairment in clinically isolated syndrome and multiple sclerosis10.1016/j.jns.2014.04.026 ↗
34. Thalamic Atrophy Is Associated with Development of Clinically Definite Multiple Sclerosis10.1148/radiol.13122424 ↗
35. Cerebellar lobule atrophy and disability in progressive MS10.1136/jnnp-2017-316448 ↗
36. Inglese, M., Petracca, M., Mormina, E., Achiron, A., Straus-Farber, R., Miron, S., Fabian, M., Krieger, S., Miller, A., and Lublin, F. (2017). Cerebellar volume as imaging outcome in pro-gressive multiple sclerosis. PLoS ONE, 12.10.1371/journal.pone.0176519 ↗
37. Cerebellar pathology and disability worsening in relapsing-remitting multiple sclerosis: A retrospective analysis from the CombiRx trial10.1111/ene.15157 ↗
38. Wilkins, A. (2017). Cerebellar Dysfunction in Multiple Sclerosis. Front. Neurol., 8.10.3389/fneur.2017.00312 ↗
39. Commercial volumetric MRI reporting tools in multiple sclerosis: A systematic review of the evidence10.1007/s00234-022-03074-w ↗
40. Technical and clinical validation of commercial automated volumetric MRI tools for dementia diagnosis-a systematic review10.1007/s00234-021-02746-3 ↗